Encapsulated mitochondria to reprogram the metabolism of M2-type macrophages for anti-tumor therapy

Yonghui Wang, Chang Liu, Xiaodong Ma, Anne Filppula, Youbin Cui, Jiangbin Ye*, Hongbo Zhang*

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

2 Downloads (Pure)

Abstract

M2-type macrophages (M2Φ) play a pro-tumorigenic role and are closely associated with tumor development, where metabolic dysregulation exacerbates the immunosuppressive tumor microenvironment and fosters tumor growth. Mitochondria serve as the regulatory center of cellular metabolism, yet effective methods to modulate M2Φ mitochondria within the tumor microenvironment remain lacking. In this study, we developed a technique utilizing the bio-encapsulation of mitochondria in Zeolitic Imidazolate Framework-8 (ZiF-8), referred to as Mito@ZiF-8. Our findings demonstrated that this coating protects intact mitochondria and preserves their bioactivity over an extended period after isolation. We successfully delivered Mito@ZiF-8 into M2Φ, which inhibited the secretion of pro-inflammatory factors, promoted the release of anti-inflammatory factors, and reprogrammed M2Φ metabolism. This innovative approach has the potential to reduce breast cancer cell metastasis and enhance sensitivity to chemotherapy drugs such as 6-thioguanine, cisplatin, and doxorubicin (Dox). Mito@ZiF-8 aims to reprogram the M2Φ microenvironment to support anti-tumor therapies, offering a novel strategy for improving the effectiveness of breast cancer treatment.

Original languageEnglish
Pages (from-to)20925-20939
Number of pages15
JournalNanoscale
Volume16
Issue number45
DOIs
Publication statusPublished - 7 Dec 2024
MoE publication typeA1 Journal article-refereed

Fingerprint

Dive into the research topics of 'Encapsulated mitochondria to reprogram the metabolism of M2-type macrophages for anti-tumor therapy'. Together they form a unique fingerprint.

Cite this